Haukeland University Hospital — Biomedical Watch V2

Traitements4programmes

Essais2liés

Publications13liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
IvIgInflammatory cytokines in the cerebrospinal fluid may contribute to the new muscle weakness, fatigue and pain experienced by patients with post-polio syndrome. Intravenousimmunoglobulin (IvIg) reduces this inflammation. The purpose of this study is to investigate the clinical effect of IvIg in post-polio syndrome.	Myopathies	Phase 2	Traitement symptomatique		À vérifier
N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's DiseaseThe goal of this clinical trial is to learn if orally administered nicotinamide riboside works to slow the progression of early Alzheimer disease in adults. It will also learn about the safety of drug nicotinamide riboside. The main questions it aims to answer are: * Does drug nicotinamide riboside slow the progression of Alzheimer disease as measured by the Clinical Dementia Rating scale. * What medical problems do participants have when taking drug nicotinamide riboside? Researchers will compare drug nicotinamide riboside to a placebo (a look-alike substance that contains no drug) to see if nicotinamide riboside works to treat early Alzheimer disease. Participants will: * Take drug nicotinamide ribosie or a placebo every day for 24 months * Visit the clinic once every 26 weeks for checkups and tests	Alzheimer	Phase 2	Ralentissement de la progression	Norway	À vérifier
IvIgInflammatory cytokines in the cerebrospinal fluid may contribute to the new muscle weakness, fatigue and pain experienced by patients with post-polio syndrome. Intravenousimmunoglobulin (IvIg) reduces this inflammation. The purpose of this study is to investigate the clinical effect of IvIg in post-polio syndrome.	Myopathies	Phase 2	Traitement symptomatique		À vérifier
N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's DiseaseThe goal of this clinical trial is to learn if orally administered nicotinamide riboside works to slow the progression of early Alzheimer disease in adults. It will also learn about the safety of drug nicotinamide riboside. The main questions it aims to answer are: * Does drug nicotinamide riboside slow the progression of Alzheimer disease as measured by the Clinical Dementia Rating scale. * What medical problems do participants have when taking drug nicotinamide riboside? Researchers will compare drug nicotinamide riboside to a placebo (a look-alike substance that contains no drug) to see if nicotinamide riboside works to treat early Alzheimer disease. Participants will: * Take drug nicotinamide ribosie or a placebo every day for 24 months * Visit the clinic once every 26 weeks for checkups and tests	Alzheimer	Phase 2	Ralentissement de la progression	Norway	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease	Alzheimer	Phase 2	NCT07741071	N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease	NOT_YET_RECRUITING
IvIg	Myopathies	Phase 2	NCT00231439	Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg)	COMPLETED

Publications

13

Molécule	Indication / population	Titre	Journal	Date
IvIg		Anti-GAD65 antibody-associated cerebellar ataxia in a young adult with type 1 diabetes: a case report and literature review.	Diabetology international
IvIg		The economic value of self-administered subcutaneous immunoglobulin G (SCIg) in Canada: a scoping review.	Journal of medical economics
IvIg		SARS-CoV-2-induced IgG repertoires shape T cell responses, microRNA regulation, and autoreactivity according to disease severity.	Journal of translational autoimmunity
IvIg		When Neurodevelopment Meets Autoimmunity: Pemphigus Foliaceus in Rett Syndrome Expands the Clinical Spectrum-A Case Report.	International journal of molecular sciences
IvIg		Guillain-Barré syndrome with bilateral extensor plantar responses: A rare case report.	Journal of family medicine and primary care
IvIg		A case report of Good syndrome: Diarrhea and dyspnea.	Medicine
IvIg		Knowledge graph visualization and bibliometric analysis of research on coronary artery lesions in Kawasaki disease.	Medicine
IvIg		Immune-Related Adverse Events From Checkpoint Inhibitors: An Evidence-Based Management Review.	Critical reviews in oncology/hematology
IvIg		Intravenous Immunoglobulin-Resistant Kawasaki Disease: Diagnosis, Mechanisms, and Clinical Management.	European journal of pharmacology
IvIg		Fulminant toxic epidermal necrolysis induced by pucotenlimab in a patient with lung adenocarcinoma: a case report.	Frontiers in oncology
IvIg		Guillain-Barré Syndrome Following Dengue Infection: A Case Series with Review of Literature.	Annals of neurosciences
IvIg		Early postoperative onset of immune thrombocytopenia in rheumatoid arthritis with concomitant systemic lupus erythematosus: a case report.	Modern rheumatology case reports
IvIg		Adjuvant intravenous immunoglobulin in elderly sepsis: a randomized controlled study of mortality, organ function, and inflammation.	Frontiers in medicine